Novo Nordisk A/S
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Maziar Mike Doustdar
- Full Time Employees
- 68,794
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Novo Alle 1 Bagsvaerd CR Denmark 2880
- IPO Date
- Apr 30, 1981
- CIK
- 0000353278
- Website
- novonordisk.com
- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
Company News
Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'
Citi flags GLP-1 prescription slowdown at Novo Nordisk, reiterates 'sell'
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany
Novo Nordisk launches Wegovy weight-loss pill in Germany
GLP-1 weight loss drugs effective even at low starter doses
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Novo Nordisk stock falls as Deutsche Bank downgrades shares to sell
Novo Nordisk Stock Is Downgraded to Sell, and GLP-1s Aren't the Reason
Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns
GLP-1 maker hit with 'sell' rating as 2027 revenue cliff fears mount
Ozempic maker Novo Nordisk downgraded to sell after 70% stock-price dive from peak
China drug regulator accepts Novo Nordisk's application for oral Wegovy
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal
2 Stocks That Could Capitalize on the GLP-1 Boom
Eli Lilly vs Novo Nordisk: One Winner in The Weight-Loss Drug Gold Rush
Novo Resources Releases Updated Corporate Presentation